// App-Quantinova.ai

: Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Researchers

Presenter

  • Elena Castro

Principal Investigators

  • Shahneen Sandhu

  • David Olmos

  • Gerhardt Attard

  • Marniza Saad

  • Andrea Juliana Gomes

  • Dana E. Rathkopf

  • Matthew Raymond Smith

  • Taek Won Kang

  • Felipe Melo Cruz

  • Umberto Basso

  • Gary Mason

  • Adam del Corral

  • Shiva Dibaj

  • Daphne Wu

  • Brooke Diorio

  • Angela Mennicke Lopez- Gitlitz

  • Deniz Tural

  • Eric Jay Small

Medical Centers

  • Janssen Research and Development, LLC, Spring House, PA

  • Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain

  • The Institute of Cancer Research, King's College, London, United Kingdom

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea,

  • Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey

  • Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

  • Instituto Oncologico Veneto, Padova, Italy

  • University of California, San Francisco, San Francisco, CA

  • Liga Norte Riograndense Contra o Cncer, Natal, Brazil

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Instituto Brasileiro de Controle do Cancer, Mooca, Brazil

  • Hospital Virgen de la Victoria, Malaga, Spain

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

Locations

  • Malaysia

  • Republic of South Korea

  • Italy

  • Turkey

  • Canada

  • Spain

  • Australia

  • United Kingdom

  • Brazil

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • BRCA mutation

  • Hormone receptor

Drug/Treatment

  • CB-7598

  • Prednisone

  • Niraparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03748641

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved